Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

Regulatory agencies around the world have been using flexible requirements for approval of new drugs, especially for cancer drugs. The US Food and Drug Administration (FDA) is mostly the first agency to approve new drugs worldwide, mainly due to the faster terms of the accelerated pathway and breakt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Tatiane Bomfim, Buss, Lewis, Wayant, Cole, Nobre, Moacyr Roberto Cuce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380631/
https://www.ncbi.nlm.nih.gov/pubmed/32706800
http://dx.doi.org/10.1371/journal.pone.0236345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380631/
https://www.ncbi.nlm.nih.gov/pubmed/32706800
http://dx.doi.org/10.1371/journal.pone.0236345

Ejemplares similares